CD19 and diffuse large B-cell lymphoma: Three commercial CD19-targeted CAR-T products, including Axicabtagene ciloleucel (Axi-cel), Tisa-cel and Lisocabtagene Maraleucel (Liso-cel), have been approved for adult patients with R/R DLBCL, HGBCL, and FL-derived DLBCL, who have received two or more lines of systemic therapy.